Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study,The Lancet Haematology

当前位置： X-MOL 学术 › Lancet Haematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
The Lancet Haematology ( IF 15.4 ) Pub Date : 2024-06-15 , DOI: 10.1016/s2352-3026(24)00166-2
Kim M Linton ₁ , Umberto Vitolo ₂ , Wojciech Jurczak ₃ , Pieternella J Lugtenburg ₄ , Emmanuel Gyan ₅ , Anna Sureda ₆ , Jacob Haaber Christensen ₇ , Brian Hess ₈ , Hervé Tilly ₉ , Raul Cordoba ₁₀ , David John Lewis ₁₁ , Craig Okada ₁₂ , Martin Hutchings ₁₃ , Michael Roost Clausen ₁₄ , Juan-Manuel Sancho ₁₅ , Tara Cochrane ₁₆ , Sirpa Leppä ₁₇ , Martine E D Chamuleau ₁₈ , Diana Gernhardt ₁₉ , Işıl Altıntaş ₂₀ , Yan Liu ₁₉ , Tahamtan Ahmadi ₁₉ , Minh H Dinh ₂₁ , Daniela Hoehn ₁₉ , Elena Favaro ₂₂ , Brian Elliott ₁₉ , Catherine Thieblemont ₂₃ , Julie M Vose ₂₄

Affiliation

The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK.
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
MSC National Research Institute of Oncology, Kraków, Poland.
Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands.
Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Tours, CIC INSERM U1415, Tours, France.
Clinical Hematology Department, Institut Català d'Oncologia-L'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
Odense University Hospital, Odense, Denmark.
Medical University of South Carolina, Charleston, SC, USA.
Centre Henri Becquerel, Université de Rouen, Rouen, France.
Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain.
University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK.
Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.
Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
Vejle Hospital, Vejle, Denmark.
Catalan Institute of Oncology (ICO), ICO Hospital Germans Trias i Pujol, Badalona, Spain.
Gold Coast University Hospital, Southport, QLD, Australia.
University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands.
Genmab, Plainsboro, NJ, USA.
Genmab, Utrecht, Netherlands.
AbbVie, North Chicago, IL, USA.
Genmab, Copenhagen, Denmark.
Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France.
University of Nebraska Medical Center, Omaha, NE, USA.

A standard of care and optimal duration of therapy have not been established for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was to evaluate epcoritamab, a novel CD3 × CD20 bispecific antibody, in the third-line and later setting of follicular lymphoma.

中文翻译：

复发或难治性滤泡性淋巴瘤患者的 Epcoritamab 单药治疗（EPCORE NHL-1）：单臂、多中心研究的 2 期队列

尚未确定多重复发或难治性滤泡性淋巴瘤患者的护理标准和最佳治疗持续时间。本研究的目的是评估 epcoritamab，一种新型 CD3 × CD20 双特异性抗体，在滤泡性淋巴瘤的三线及后期情况下。

更新日期：2024-06-15

点击分享查看原文

点击收藏

阅读更多本刊新发论文